Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.

Procaccio L, Giordano G, Nichetti F, Milella M, Pretta A, Iacono D, Niger M, Casalino S, Vivaldi C, De Vita F, Pusceddu V, Landriscina M, Di Paolo G, Sperotto S, Masucci M, Tortora G, Bianco R, Vasile E, Zaniboni A, Miceli CC, Ongaro E, Giommoni E, Tinè G, Barsotti G, Marchesi S, Di Marco M, Ortolani S, Aprile G, Scartozzi M, Bergamo F, Melisi D, Lonardi S

Open source

DOI: 10.1093/oncolo/oyag085
Published: 2026 Mar 9
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag085,
  title = {Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.},
  author = {Procaccio L and Giordano G and Nichetti F and Milella M and Pretta A and Iacono D and Niger M and Casalino S and Vivaldi C and De Vita F and Pusceddu V and Landriscina M and Di Paolo G and Sperotto S and Masucci M and Tortora G and Bianco R and Vasile E and Zaniboni A and Miceli CC and Ongaro E and Giommoni E and Tinè G and Barsotti G and Marchesi S and Di Marco M and Ortolani S and Aprile G and Scartozzi M and Bergamo F and Melisi D and Lonardi S},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag085},
  url = {https://doi.org/10.1093/oncolo/oyag085}
}

RIS

TY  - JOUR
TI  - Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.
AU  - Procaccio L
AU  - Giordano G
AU  - Nichetti F
AU  - Milella M
AU  - Pretta A
AU  - Iacono D
AU  - Niger M
AU  - Casalino S
AU  - Vivaldi C
AU  - De Vita F
AU  - Pusceddu V
AU  - Landriscina M
AU  - Di Paolo G
AU  - Sperotto S
AU  - Masucci M
AU  - Tortora G
AU  - Bianco R
AU  - Vasile E
AU  - Zaniboni A
AU  - Miceli CC
AU  - Ongaro E
AU  - Giommoni E
AU  - Tinè G
AU  - Barsotti G
AU  - Marchesi S
AU  - Di Marco M
AU  - Ortolani S
AU  - Aprile G
AU  - Scartozzi M
AU  - Bergamo F
AU  - Melisi D
AU  - Lonardi S
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag085
UR  - https://doi.org/10.1093/oncolo/oyag085
ER  -

APA

L, P., G, G., F, N., M, M., A, P., D, I., M, N., S, C., C, V., F, D. V., V, P., M, L., G, D. P., S, S., M, M., G, T., R, B., E, V., A, Z., CC, M., E, O., E, G., G, T., G, B., S, M., M, D. M., S, O., G, A., M, S., F, B., D, M., & S, L. (2026). Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.. The oncologist. https://doi.org/10.1093/oncolo/oyag085

Source records

pubmed · retrieved 2026-09-26T19:33:33.108Z